News

09 Dec: New data demonstrates that federal price controls on medicines are already driving decisions to delay or not launch new therapies in Canada, reduce clinical trial investments and stall compassionate access and patient support programs

Life Sciences Ontario commissioned Research Etc., an established Toronto research firm, to conduct a survey of pharmaceutical and other life sciences leaders on the Canadian price regulations policy environment. Preliminary results of the survey are now available, drawing on 23 responses from unique organizations representing Canadian and global pharma leaders….

22 Nov: LSO Announces Recipients of the 2020 LSO Awards

TORONTO– LSO today announced the recipients of its 2020 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontario’s life sciences sector. The awards will be presented during LSO’s Celebration of Success Awards Dinner at Toronto’s Liberty Grand, February 26, 2020. The 2020 awardees are as follows: Lifetime Achievement…

19 Nov: Sizing up Canada’s biomedical field- The Globe and Mail

Canadian researchers have given the world insulin, pacemakers and the discovery of stem cells, and are making headway in a number of biomedical fields, including artificial intelligence, medical imaging, quantum computing and cannabis-based treatments. Aside from research and innovation, the potential for economic success in the biomedical field is massive,…

12 Aug: Future of life sciences research in Canada seriously threatened by federal government’s new patented drug pricing regulations

Complicated new regulations will set maximum allowable prices for new medicines too low to justify research and launch of medicines in Canada Changes will also exacerbate potential for mass diversion of lower-priced Canadian medicines to the United States EDMONTON, TORONTO and MONTREAL, Aug. 9, 2019 /CNW/ – The federal government’s new regulations for setting the maximum allowable…